GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (MEX:GH) » Definitions » Valuation Rank

Guardant Health (MEX:GH) Valuation Rank


View and export this data going back to 2019. Start your Free Trial

What is Guardant Health Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Guardant Health Valuation Rank Related Terms

Thank you for viewing the detailed overview of Guardant Health's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (MEX:GH) » Definitions » Valuation Rank
Comparable Companies
NEOG SHC RDNT NEO NTRA MYGN OPK TWST FLGT CSTL TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
GH:USA 5GH:Germany
Address
3100 Hanover Street, Palo Alto, CA, USA, 94304
Website
https://www.guardanthealth.com
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.